Pablo Cagnoni's Email & Phone Number

💼 Past Experience

Pablo Cagnoni's work experience with Onyx Pharmaceuticals:President at Onyx Pharmaceuticals from October 2013 to April 2015 (1 year 7 months) in San Francisco Bay Area. EVP and Global Head R&D and Technical Operations, at Onyx Pharmaceuticals from March 2013 to October 2013 (8 months) in San Francisco Bay Area.

🎓 Education

- Completed his studies in Business Administration (B.A.) in 2003 at the University of Buenos Aires -Since then he has worked in companies such as Banco Indusero, Goutrak, andhnacorp-He has an effective interest in education and has had many projects in the field of learning and development-Achievements in education include being a delegate to the Argentine Congress of Educators and an Invited speaker at the International conference "Learning and Development in Latin America" (Madrid, Spain, in 2011)-Pablo Cagnoni can speak both English and SpanishPablo Cagnoni has a long history of education and working experience. He has studied at the University of Buenos Aires where he earned his B.A. in Business Administration in 2003. While at the University of Buenos Aires, Pablo Cagnoni worked in companies such as Banco Indusero, Goutrak, and Heineken. He has had many projects in the area of learning and development, and has achieved successes such as being a delegate to the Argentine Congress of Educators and an Invited speaker at the International conference " Learning and Development in Latin America" (Madrid, Spain, in 2011). Pablo Cagnoni can speak both English and Spanish.

💡 Technical & Interpersonal Skills

Pablo Cagnoni has experience in the Healthcare industry, most notably as President and Chief Executive Officer of Tizona Therapeutics. In this role, he led the development and launch of a new innovative global product line from Tizona Therapeutics, Inc. Pablo Cagnoni also had experience in the Pharmaceutical industry, most notably as President and Chief Executive Officer of Onyx Pharmaceuticals. In this role, he led the development and launch of Onyx Pharmaceuticals' novel tablet product line.